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Purpose: The goal of this study was to identify baseline prognostic factors of out-
come in ankle osteoarthritis patients after intra-articular hyaluronic acid injection. 
Materials and Methods: Patients with ankle osteoarthritis who received hyaluron-
ic acid injection therapy were retrospectively reviewed. Each patient received 
weekly intra-articular hyaluronic acid injections (2 mL) for 3 weeks. Six predictors 
including gender, age, symptom duration, radiographic osteoarthritis stage, radio-
graphic subchondral cyst, and fracture history were evaluated. Visual analogue 
scale (VAS) and patient satisfaction were evaluated as outcome measures. These 
predictors and outcome measurements were included in a logistic regression model 
for statistical analysis. Results: Total of 40 consecutive patients (21 male, 19 fe-
male) were included in this study. Mean age was 60.6. Average follow up period 
was 13 months. The mean VAS recorded 3, 6, and 12 months after the first injection 
was 3.6 (SD 2.54, p<0.001), 4.33 (SD 2.9, p<0.001), and 5.3 (SD 2.7, p=0.0071), 
respectively, when compared to baseline VAS. Early stage disease was identified as 
an independent predictor associated with ‘positive VAS outcome’ at 3 and 6 months. 
Early stage disease and duration of pain less than 1 year were independent predic-
tors associated with higher satisfaction. Conclusion: While hyaluronic acid injec-
tion for ankle osteoarthritis is a safe and effective treatment, careful selection of pa-
tients should be made according to the above prognostic predictors.
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INTRODUCTION
 
While the prevalence of ankle joint osteoarthritis (OA) is approximately <1% of 
the adult population, far lower than knee joint OA, its disease and socioeconomic 
burden cannot be overlooked.1 Nearly 70% of ankle OA is post-traumatic, affect-
ing a relatively younger population compared to other joints.2-4 Ankle OA thus hin-
ders the performances at work and athletics in this otherwise healthy population.5 
Treatment methods for ankle OA differ according to disease severity and activity 
level of the patient. These include exercise, weight loss, orthosis, simple analgesics, 
non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injec-
tion and surgery. Surgical treatments, which include total ankle arthroplasty and ankle 
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as follows; 1) patients who had prior history of surgery for 
ankle OA, such as arthroscopic debridement, 2) bilateral an-
kle OA, 3) patients with prior intra-articular injection history, 
including HA or corticosteroid, 4) any other diagnosis for an-
kle pain, such as rheumatoid arthritis, 5) patients unable to 
complete the 3 week treatment protocol, and 6) patients lost 
during outpatient clinic follow up for at least 12 months or 
unwilling to fill out our questionnaires for data collection. 
All patients in this study visited our clinic at least 7 times; 
baseline (with first injection), weekly second and third in-
jection, 1 week after third injection, and 3, 6, and 12 month 
visits after the first injection. At baseline, bilateral, weight-
bearing ankle radiographs were taken (AP and lateral view). 
Information was gathered regarding demographic data, med-
ical and surgical history, duration of ankle pain, medication 
history and current level of pain using a 100 mm visual ana-
logue scale (VAS) by a blinded observer who did not partici-
pate in this study. During each visit, changes in VAS were 
recorded. Any adverse effects were also recorded if present.   
Treatment protocol
Each patient received weekly intra-articular HA injections 
(20 mg/2 mL, MW 3 MDa) for 3 weeks. The antero-medial 
portal for ankle arthroscopy was used as an injection site. 
Aseptic principles were followed during the injections.
Outcome measures and groups for analysis
Primary outcome measure for evaluating effectiveness of in-
tra-articular HA injection was pain, measured by 100 mm 
VAS during each visit. We have used 4 respective endpoints; 
1 week after third injection, and 3, 6, 12 months after the 
first injection. Patients were dichotomized into ‘positive out-
come’ group (50% or more decrease in VAS compared to 
baseline VAS) and ‘negative outcome’ group (negative or 
no change in VAS, or <50% improvement in VAS com-
pared to baseline VAS) for each end point. Secondary out-
come measure was assessed by subjectively asking each 
patient’s level of satisfaction with the question “How satis-
fied are you with the injected ankle?” 1 year after injection. 
The response was recorded using a 4 point Likert scale (1; 
completely satisfied, 2; satisfied, 3; somewhat satisfied, and 
4; not satisfied). Patients were also dichotomized into ‘sat-
isfied’ group (1 and 2) and ‘dissatisfied’ group (3 and 4). 
 
Predictors
The following factors were included in the statistical analy-
sis as independent variables.
fusion, carry numerous complications and are only indicated 
for end stage disease. Ankle OA patients with milder stages 
are relatively young, not yet surgical candidates, and many 
wish to be active without the burden of pain medications.6 
Viscosupplementation with hyaluronic acid (HA) may be 
an effective treatment modality for such ankle OA patients.7 
Intra-articular HA injection has been approved by the U.S. 
Food and Drug Administration for the treatment of knee 
OA in 1997, and has since been used for treatment of OA in 
many other joints, including the ankle.7-10 The intra-articular 
injection of HA replaces lost HA in the arthritic joint and 
possibly stimulates the endogenous production of HA, pro-
viding symptomatic relief and improving biomechanical 
function.11 Several authors have reported favorable short 
term results after intra-articular HA injection in ankle OA 
patients.12,13 The optimal indications for this treatment, how-
ever, have not yet been established. The goal of this study 
was to identify prognostic predictors in ankle OA patients 
that are easily identifiable in an outpatient clinic setting af-
ter intra-articular HA injection. 
MATERIALS AND METHODS
　　　
Study design
Consecutive patients clinically diagnosed with ankle OA 
who had received intra-articular HA injection therapy were 
retrospectively reviewed. The study was carried out in a 
single tertiary institution outpatient clinic. Before intra-artic-
ular HA injection, all patients signed a consent form fully 
disclosing the risk and benefits of the treatment. The study, 
along with the treatment protocol, was approved by our In-
stitutional Review Board. Inclusion criteria were as fol-
lows; 1) patients diagnosed with ankle OA by clinical and 
radiologic evidence, 2) patients who had discontinued pain 
control medication (anti-inflammatory drugs and analge-
sics) for at least 12 months after intra-articular HA injec-
tion, excluding intermittent rescue medication, 3) self-am-
bulatory patients able to walk at least 50 meters without the 
assistance of a wheel chair or crutches, and 4) patients who 
were followed by our outpatient clinic for at least 12 months 
after intra-articular HA injections. Rescue medication was 
defined as acetaminophen (<4 g/day) administered not for 
more than 3 consecutive days, and no more than 10 days per 
month. All patients receiving intra-articular HA injections 
had no symptomatic improvement with oral NSAIDs for at 
least 3 months prior to HA injection. Exclusion criteria were 
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Statistical analysis
Mean VAS values from each time point were compared us-
ing Wilcoxon signed-rank test. The dichotomized variables 
were assessed using Fisher’s exact test for changes in VAS 
and satisfaction. Multivariable logistic regression model was 
used to identify independent predictors of prognosis for sat-
isfaction. A p value of <0.05 was defined as significant. Sta-
tistical Analysis Software version 9.2 (SAS Institute Inc., 
Cary, NC, USA) was used for data analysis. 
 
RESULTS
 
Patient demographics
A total of 40 consecutive patients (21 male, 19 female) met 
our criteria for this study. The mean age was 60.6 years (range 
35--80). The mean duration of pain was 49.63 months (SD 
91.66). Takakura OA classification revealed 16 stage I pa-
tients (40%), 12 stage II patients (30%), 5 stage III patients 
(12.5%), and 7 stage IV patients (17.5%). Seven out of 40 
patients (18%) had a history of fracture around the ankle. 
Six out of 40 patients (15%) had radiographic subchondral 
cyst formation. 
Clinical efficacy
The overall mean VAS at baseline was 8.1 (SD 1.533). On 
short term follow up, where VAS was recorded a week after 
the first, second, and third injection, the mean VAS decreased 
to 5.3 (SD 1.636, p<0.001), 3.53 (SD 2.1, p<0.001), and 3.17 
(SD 2.2, p<0.001), respectively, when compared to baseline 
VAS (Fig. 1A). On longer term follow up, where VAS was 
recorded 3, 6, and 12 months after the first injection, the 
Age
The mean age of the sample patients (60.6) was used as a 
cutoff point to dichotomize all patients into two groups. As 
a result, 19 patients were included in the <60 group, and 21 
in the ≥60 group.  
Gender
Twenty-one patients were male, and 19 patients were female.
Duration of pain
Sample patients were dichotomized into two groups; pain 
lasting ≤12 months and >12 months. As a result, 24 patients 
had pain duration of >12 months, and 16 patients had pain 
duration of ≤12 months.
Staging of ankle OA
Ankle radiographs of all patients were evaluated using 
Takakura classification (stage I; early sclerosis and osteo-
phyte formation without joint space narrowing, stage II; 
narrowing of medial joint space, stage III; partial oblitera-
tion of joint space, and stage IV; obliteration of whole joint 
space).14 Results were dichotomized as ‘early stage’ group, 
which included stage I and II ankles, and ‘late stage’ group, 
which included stage III and IV ankles. Twenty-eight pa-
tients were allocated in the ‘early stage’ group, and 12 pa-
tients were allocated in the ‘late stage’ group.
History of fracture
Seven patients had a history of fracture around the ankle joint.
Presence of radiographic subchondral cyst
Six patients showed radiographic subchondral cysts. 
Fig. 1. Histogram of VAS change according to time. (A) Short term changes after intra-articular HA injection. (B) Long term changes after intra-articular HA 
injection, compared to baseline VAS. Baseline, before injection; Week 1, 1 week after first injection; Week 2, 1 week after second injection; Week 3, 1 week 
after third injection; VAS, visual analogue scale; HA, hyaluronic acid.
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VAS were more likely to have early stage disease (Takakura 
stage 1 or 2, p=0.0032) (Table 1). Other predictors did not 
show statistically significant differences. At 6 months after 
the first injection, 21 patients showed ‘positive outcomes’ 
in VAS (52.5%), while 19 patients showed ‘negative out-
comes’ (47.5%). Patients with ‘positive outcome’ in VAS 
were also more likely to have early stage disease (Takakura 
stage 1 or 2, p=0.005) (Table 2). At 12 months after the first 
injection, 16 patients showed ‘positive outcomes’ in VAS 
(40%), while 24 patients showed ‘negative outcomes’ (60%). 
No predictors showed statistically significant differences 
(Table 3). 
mean VAS was 3.6 (SD 2.54, p<0.001), 4.33 (SD 2.9, p< 
0.001), and 5.3 (SD 2.7, p=0.0071), respectively, when com-
pared to baseline VAS (Fig. 1B). After 12 months follow up, 
16 patients were ‘completely satisfied’ (40%), 5 were ‘satis-
fied’ (12.5%), 5 were ‘somewhat satisfied’ (12.5%), and 14 
were ‘not satisfied’ (35%) with the treatment. 
  
Patients with positive outcome VAS vs. negative 
outcome VAS
At 3 months after the first injection, 25 patients showed 
‘positive outcomes’ in VAS (62.5%), while 15 showed ‘neg-
ative outcomes’ (37.5%). Patients with ‘positive outcome’ in 
Table 1. Patient Predictors of Prognosis According to 3 Month VAS Changes
Demographic predictors Descriptive (n)
3 month VAS change
Odds 
ratio
95% CI
p valuePositive 
(n=25, 62.5%)*
Negative 
(n=15, 37.5%)†
Lower Upper
Age (n, % of group)
     <60 (19, 48) 12 (30)   7 (18)
  1.055   0.2925   3.805 1.0000
     ≥60 (21, 53) 13 (33)   8 (20)
Sex (n, % of group)
         F (19, 48) 14 (35)   5 (13)
  2.545   0.6712   9.654 0.2037
       M (21, 53) 11 (28) 10 (25)
Pain duration 
  (n, % of group)
<12 m (11, 28)   8 (20) 3 (8)
  1.882   0.1163   2.427 0.486
 ≥12 m (29, 73) 17 (43) 12 (30)
Stage (n, % of group)
     1, 2 (28, 70) 22 (55)   6 (15)
11.000 2.246 53.863 0.0032
     3, 4 (12, 30) 3 (8)   9 (23)
Fx. history (n, % of group)
          - (33, 83) 22 (55) 11 (28)
  2.667   0.5059 14.069 0.392
       + (7, 18) 3 (8)   4 (10)
Radiographic cyst 
  (n, % of group)
       + (6, 15)   4 (10) 2 (5)
  1.238   0.1979     7.7744 1.0000
          - (34, 85) 21 (53) 13 (33)
VAS, visual analogue scale; CI, confidence interval.
*50% or more decrease in VAS compared to baseline VAS.
†Negative or no change in VAS, or <50% improvement in VAS compared to baseline VAS.
Table 2. Patient Predictors of Prognosis According to 6 Month VAS Changes
Demographic predictors Descriptive (n)
6 month VAS change
Odds 
ratio
95% CI
p valuePositive 
(n=21, 52.5%)*
Negative 
(n=19, 47.5%)†
Lower Upper
Age (n, % of group)
     ≥60 (21, 53) 10 (25)   9 (23)
  1.010   0.2914   3.501 1.0000
     <60 (19, 48) 11 (28) 10 (25)
Sex (n, % of group)
         F (19, 48) 11 (28)   8 (20)
  1.513   0.4332   5.281 0.5450
       M (21, 53) 10 (25) 11 (28)
Pain duration 
  (n, % of group)
<12 m (11, 28)   7 (18)   4 (10)
  1.875   0.4494   7.823 0.4882
 ≥12 m (29, 73) 14 (35) 15 (38)
Stage (n, % of group)
      1, 2 (28, 70) 19 (48)   9 (23)
10.556 1.903 58.553 0.0050
      3, 4 (12, 30) 2 (5) 10 (25)
Fx. history (n, % of group)
          - (33, 83) 19 (48) 14 (35)
  3.393   0.5724 20.112 0.2258
       + (7, 18) 2 (5)   5 (13)
Radiographic cyst 
  (n, % of group)
       + (6, 15) 2 (5)   4 (10)
    0.3947   0.0635   2.455 0.3976
          - (34, 85) 19 (48) 15 (38)
VAS, visual analogue scale; CI, confidence interval.
*50% or more decrease in VAS compared to baseline VAS.
†Negative or no change in VAS, or <50% improvement in VAS compared to baseline VAS.
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den that the disease places on the daily activities of patients. 
These patients may benefit from non-surgical treatment mo-
dalities such as intra-articular HA injection that may delay 
end-stage surgery. Currently, there is no consensus or guide-
line highlighting who will actually benefit from intra-articu-
lar HA injection in ankle OA patients. The goal of this study 
was to identify independent prognostic predictors in ankle 
OA patients after intra-articular HA injection. We have ana-
lyzed predictors that are easily identifiable in an outpatient 
clinic, in order for our results to be directly applicable in 
clinic. As a result, patients with shorter symptom duration 
(≤12 months) and early stage disease (Takakura stage 1, 2) 
were more likely to show improvement in VAS and satis-
Patients with ‘satisfied’ vs. ‘dissatisfied’ results
At 12 months, patients with ‘satisfactory’ outcomes (patients 
who answered either ‘completely satisfied’ or ‘satisfied’) 
were more likely to have early stage disease (Takakura stage 
1 or 2, p=0.0015) (Table 4). Logistic regression analysis 
identified pain duration of ≤12 months, and early stage dis-
ease to be independent predictors associated with ‘satisfac-
tory’ results (Table 5).
DISCUSSION
Ankle OA remains a major clinical problem due to the bur-
Table 3. Patient Predictors of Prognosis According to 12 Month VAS Changes
Demographic predictors Descriptive (n)
12 month VAS change
Odds 
ratio
95% CI
p valuePositive 
(n=16, 40%)*
Negative 
(n=24, 60%)†
Lower Upper
Age (n, % of group) 
     <60 (19, 48) 10 (25)   9 (23)
2.778 0.7518 10.264 0.1965
     ≥60 (21, 53)   6 (15) 15 (38)
Sex (n, % of group)
         F (19, 48)   8 (20) 11 (28)
1.182 0.3328   4.197 1.0000
       M (21, 53)   8 (20) 13 (33)
Pain duration (n, % of group)
<12 m (11, 28) 3 (8)   8 (20)
  0.4615 0.1014   2.101 0.4732
 ≥12 m (29, 73) 13 (33) 16 (40)
Stage (n, % of group)
      1, 2 (28, 70) 14 (35) 14 (35)
5.000 0.9229 27.089 0.0788
      3, 4 (12, 30) 2 (5) 10 (25)
Fx. history (n, % of group)
          - (33, 83) 14 (35) 19 (48)
1.842 0.3108 10.920 0.6808
       + (7, 18) 2 (5)   5 (13)
Radiographic cyst 
  (n, % of group)
       + (6, 15) 2 (5)   4 (10)
  0.7143 0.1146   4.453 1.0000
          - (34, 85) 14 (35) 20 (50)
VAS, visual analogue scale; CI, confidence interval.
*50% or more decrease in VAS compared to baseline VAS.
†Negative or no change in VAS, or <50% improvement in VAS compared to baseline VAS.
Table 4. Patient Predictors of Prognosis According to Satisfaction at 12 Months
Demographic predictors Descriptive (n)
Satisfaction
Odds 
ratio
95% CI
p valuePositive 
(n=19, 48%)*
Negative 
(n=21, 53%)†
Lower Upper
Age  (n, % of group)
    <60 (19, 48) 10 (25)   9 (23)
  1.481 0.4251     5.163 0.7518
     ≥60 (21, 53)   9 (23) 12 (30)
Sex (n, % of group)
         F (19, 48) 10 (25)   9 (23)
  1.481 0.4251     5.163 0.7518
       M (21, 53)   9 (23) 12 (30)
Pain duration 
  (n, % of group)
≤12 m (16, 40) 11 (28)   5 (13)
  4.4 1.134     17.075 0.0515
>12 m (24, 60)   8 (20) 16 (40)
Stage (n, % of group)
     1, 2 (28, 70) 18 (45) 10 (25)
19.8 2.219 176.70 0.0015
     3, 4 (12, 30) 1 (3) 11 (28)
Fx. history (n, % of group)
          - (33, 83) 17 (43) 16 (40)
  2.656 0.4494     15.699 0.4124
       + (7, 18) 2 (5)   5 (13)
Radiographic cyst 
  (n, % of group)
       + (6, 15) 1 (3)   5 (13)
  0.1778 0.0187       1.688 0.1856
          - (34, 85) 18 (45) 16 (40)
VAS, visual analogue scale; CI, confidence interval.
*50% or more decrease in VAS compared to baseline VAS.
†Negative or no change in VAS, or <50% improvement in VAS compared to baseline VAS.
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effect. Dichotomized age does not necessarily correlate with 
ankle OA severity, with younger (<60) patients often pre-
senting with advanced stage disease.1-3 As for the history of 
fracture, our results indicate that it is not a negative prog-
nostic factor. Similar results were observed in a number of 
HA trials in ankle OA, where the diagnoses of the majority 
of patients were post-traumatic OA. Efficacy of intra-artic-
ular HA injection was similar to our results, indicating that 
post-traumatic ankle OA may not hinder the efficacy of HA 
injection.15,16 Subchondral bone cysts of the ankle often 
form as a result of osteochondral defects,20 and pain origi-
nating from bone cysts may occur due to elevated intraos-
seous pressure.21 Intra-articular HA injection in patients 
with radiographic subchondral bone cysts may have no ef-
fect, or even exacerbated cyst-originated pain by increasing 
intra-articular pressure.20
Current literature extrapolates results from knee OA stud-
ies to define predictors of prognosis.13,17,22 Lussier, et al.23 re-
ported that patients with radiographic early stage knee OA 
obtained better results compared to late stage knees after in-
tra-articular HA injection. Meta-analysis revealed that older 
(>65) patients and patients with advanced knee OA were less 
likely to benefit from HA injections.24 A study in knee OA 
patients, with purpose similar to our study, recommended 
against treating patients showing complete collapse of joint 
space with HA injections.25 While our results on disease 
stage agree with previous results shown in knee OA studies, 
symptom duration was also an independent prognostic factor. 
Biological explanation for these factors could be that, quality 
and quantity of endogenous HA in advanced OA are already 
altered, having lower molecular weight and smaller size 
compared to HA synthesized from healthy joints.26 The high 
molecular-weight HA produced from healthy joints also 
serves to insulate pain fibers.27 Longer duration of pain may 
signify that this insulation effect of HA has been inadequate 
for a long time, along with sensitization of pain fibers. 
This study is limited by the retrospective design. Although 
patients were consecutively enrolled, only patients who have 
met our inclusion criteria were reviewed. This may have left 
out some ‘non-responders’, creating a selection bias. The 
faction. To the best of our knowledge, this is the first study 
to analyze independent prognostic predictors in ankle OA 
patients after HA injection. 
A number of authors have published favorable results of 
intra-articular HA injection in the OA ankle joint.12,13,15-18 Re-
sults from our present series share the short term, favorable 
outcomes in pain score. At 3 and 6 months post-injection, 
63% and 53% of patients, respectively, showed 50% or more 
decrease in VAS compared to baseline VAS. Cohen, et al.16 
reported statistically different ankle osteoarthritis score pain 
sub-scores at 3, and 6 months post-injection compared to 
baseline, and Luciani, et al.18 reported a statistically signifi-
cant step decrease over the first 6 months. 
The exact duration of efficacy after HA injection is un-
known. Cohen, et al.16 has reported a duration of at least 3 
months, while Salk, et al.12 has reported ongoing efficacy 
over 6 months. We have followed our patients at least 12 
months in this series and have found statistically significant 
improvement of pain for up to 1 year. This ongoing pain re-
lief may have been due to direct HA effect on the intra-ar-
ticular environment as well as secondary increase in joint 
motion and resultant muscle strengthening. The peak im-
provement in our series was at 3 weeks after the first injec-
tion. Significant symptomatic relief started as early as 1 
week after the first injection. Similar therapeutic trajectory 
has been reported for knee OA, as HA was efficacious by 4 
weeks, followed by peak effectiveness at 8 weeks. Detect-
able, residual efficacy has been found up to 24 weeks post-
injection in knee OA.19
Symptom duration and radiographic stage were two in-
dependent predictors of prognosis in our series. Previous 
studies have failed to define an ideal candidate for intra-ar-
ticular HA in ankle OA patients. Sun, et al.13 attempted to 
stratify patients according to radiographic Kellgren-Law-
rence grading, but did not have sufficient number of pa-
tients to demonstrate differences: age-wise, there was sig-
nificant improvement on balance test results in the younger 
group, yet authors noted that this phenomenon may be due 
to a ceiling effect. The fact that age was not a significant 
predictor in our study may have also resulted from a ceiling 
Table 5. Independent Predictors of Prognosis of ‘Satisfactory’ Results at 12 Months Post-Injection 
Predictors 
‘Satisfactory’ results at 12 months
Odds ratio   95% CI p value
Pain duration ≤12 m   4.405 0.133--16.949 0.0322
Early stage (stage 1 and 2) 19.607     2.2--166.67 0.0075
CI, confidence interval.
Identified using logistic regression analysis.
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25. Evanich JD, Evanich CJ, Wright MB, Rydlewicz JA. Efficacy of 
intraarticular hyaluronic acid injections in knee osteoarthritis. Clin 
Orthop Relat Res 2001:173-81.
26. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of 
injections of hyaluronan and its derivatives in the treatment of os-
teoarthritis of the knee. Drug Saf  2000;23:115-30.
27. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory respons-
es to passive movements of inflamed knee joints by hylan, a hyal-
uronan derivative. Exp Brain Res 1997;116:3-9.
sample size was also small compared to knee OA studies, 
thus resulting in a weak statistical power to delineate posi-
tive and negative predictors. There are also certain differ-
ences among published data depending on the regimen, 
dosage, and type of HA injection. Other protocols may re-
sult in different results.7,20 
In conclusion, while hyaluronic acid injection for ankle 
osteoarthritis is a safe and effective treatment, careful selec-
tion of patients should be made according to the above prog-
nostic predictors. Suboptimal results may occur in ankle OA 
patients with symptom duration over 1 year and advanced 
stage disease after intra-articular HA injection.
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